IE
NVLN

Israel Englander’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Israel Englander’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,814
Closed -$14K – 4896
2019
Q3 		$14K Sell
19,814
-17,903
-47% -$13K ﹤0.01% 4098
2019
Q2 		$29K Sell
37,717
-38,387
-50% -$42.7K ﹤0.01% 3972
2019
Q1 		$94K Sell
76,104
-37,113
-33% -$42.3K ﹤0.01% 3851
2018
Q4 		$97K Sell
113,217
-118,338
-51% -$134K ﹤0.01% 3543
2018
Q3 		$685K Sell
231,555
-99,122
-30% -$351K ﹤0.01% 3073
2018
Q2 		$1.22M Buy
330,677
+295,423
+838% +$1.19M ﹤0.01% 2713
2018
Q1 		$123K Sell
35,254
-24,328
-41% -$103K ﹤0.01% 3457
2017
Q4 		$186K Buy
59,582
+13,275
+29% +$63.8K ﹤0.01% 3553
2017
Q3 		$326K Sell
46,307
-151,212
-77% -$1.21M ﹤0.01% 3030
2017
Q2 		$1.82M Sell
197,519
-130,031
-40% -$1.25M ﹤0.01% 2121
2017
Q1 		$3.52M Buy
+327,550
New +$3.35M 0.01% 1666

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Israel Englander's NVLN Position: Q4 2019 in Review

Israel Englander sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 19,814 shares — an estimated $14K sold.

Israel Englander first reported a position in NVLN in Q1 2017 and held it in 11 quarters. The position peaked at $3.52M in Q1 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Israel Englander reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Israel Englander sold 19,814 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $14K.
  • Israel Englander first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 11 quarters.
  • Israel Englander's Novelion Therapeutics Inc. Common Shares position peaked at $3.52M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Millennium Management's 13F filing for Q4 2019, filed 14 Feb 2020.